Alejandro Quiroz
About Alejandro Quiroz
Alejandro “Alex” Quiroz (age 72) has served on Ennis, Inc.’s board since 2003 and is currently an independent, non‑employee director whose term expires in 2027. He chairs the Compensation Committee and brings more than 30 years of operating and investing experience in printing and commercial real estate across the U.S. and Mexico, with notable cross‑border expertise relevant to Ennis’s supply chain and industry relationships .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Leader Graphics Arts Group (Mexico) | Founder/Investor; formed investor group | Not disclosed | Printing industry network building |
| Mexican Franchise Association | Founder and Chairman | Not disclosed | Entrepreneurial ecosystem leadership |
| Mexican Entrepreneurs Association (U.S.) | Founder and Chairman | Not disclosed | Cross‑border business leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Médica Sur (Mexico) | Independent Director | Since 2015 | First non‑U.S. hospital in Mayo Clinic network (since 2013) |
Board Governance
- Independence: The board determined Mr. Quiroz is independent under NYSE and Ennis criteria; non‑independent directors are Gary Mozina and Margaret Walters due to disclosed relationships .
- Committee assignments (FY2025): Compensation Committee Chair; not listed on Audit or Nominating/Corporate Governance .
- Attendance and engagement: Board met six times in FY2025; no incumbent director fell below 75% attendance. Directors are expected to attend annual meetings; all attended in 2024. Executive sessions occur at every regular board meeting for non‑employee directors .
- Lead independent director: The Chair of Nominating serves as lead director (John R. Blind at the time) .
- Say‑on‑pay and shareholder support: 2024 say‑on‑pay received 18,330,114 for, 934,093 against, 110,632 abstain; Mr. Quiroz’s re‑election received 18,942,142 for, 403,333 against, 29,364 abstain (broker non‑votes 3,196,444) .
Fixed Compensation
Director cash and equity compensation for Mr. Quiroz (last two fiscal years):
| Metric | FY2024 | FY2025 |
|---|---|---|
| Annual cash fees (retainer, meeting, chair, committee) ($) | $74,800 | $65,148 |
| Restricted stock grant date | 7/13/2023 | 7/18/2024 |
| Restricted stock units granted (units) | 2,709 | 2,485 |
| Grant‑date fair value ($) | $55,019 | $57,751 |
| Total director compensation ($) | $129,819 | $122,899 |
Director fee schedule (current policy highlights):
- Annual retainer: $41,580 (effective May 1, 2024) .
- Board meeting fee: $2,310 per meeting (effective May 1, 2024) .
- Committee chair fees: $6,930 (Audit, Compensation, Nominating) .
- Committee member meeting fee: $1,733 per meeting .
Stock ownership guideline for non‑employee directors: Maintain ownership equal to at least six times annual cash retainer; five years to reach compliance; hedging/pledging prohibited under Insider Trading Policy .
Performance Compensation
As Compensation Committee Chair, Mr. Quiroz oversees the executive long‑term incentive program (RSUs) tied to multi‑year performance. Current three‑year performance period (FY2025–FY2027) metrics and vesting schedules:
| Metric | Threshold | Target | Maximum | Vesting at Level |
|---|---|---|---|---|
| Cumulative EBITDA (FY2025–FY2027) | $170,784,079 | $243,977,255 | $317,170,432 | 70%→130% of metric‑linked RSUs |
| Average ROE (FY2025–FY2027) | 9.0% | 12.9% | 16.8% | 70%→130% of metric‑linked RSUs |
| TSR modifier (applied if EBITDA/ROE below target) | ≤33.3%ile → 70% | 33.3–66.6%ile → 100% | >66.6%ile → 130% | Relative to Equilar peer set |
Peer group used for FY2025–FY2027 TSR modifier (examples): Ashland (ASH), H.B. Fuller (FUL), Minerals Technologies (MTX), Quaker Chemical (KWR), Stepan (SCL), etc. . For salary benchmarking the committee referenced Equilar peer data (2024 list includes ARC Document Solutions, Deluxe, Glatfelter, Mativ, Quaker Chemical, Stepan, etc.) .
Other Directorships & Interlocks
| Company | Type | Role | Interlocks/Notes |
|---|---|---|---|
| Médica Sur (Mexico) | Public company (healthcare) | Independent Director | No disclosed compensation committee interlocks at Ennis in FY2025/FY2024 |
- Compensation Committee Interlocks: None disclosed in FY2025 or FY2024; committee comprised of independent directors (Blind, Clemens, Quiroz as Chair) .
Expertise & Qualifications
- Printing industry operator/investor; cross‑border legal and cultural insights for U.S.–Mexico business (founder/investor in printing entities; real estate partnerships) .
- Governance leadership through compensation chair role; experience founding and leading business associations that strengthen entrepreneurial ecosystems .
- Board diversity and governance alignment objectives explicitly noted by Ennis’s Nominating Committee; Mr. Quiroz contributes to Board diversity goals .
Equity Ownership
| Item | Value |
|---|---|
| Shares beneficially owned (as of May 16, 2025) | 8,557 shares (unpledged) |
| Ownership as % of shares outstanding | <1% (25,795,161 shares outstanding) |
| Outstanding director stock awards (units, as of Feb 28, 2025) | 5,125 units |
| Insider Trading Policy | Hedging and pledging prohibited for directors |
Governance Assessment
- Strengths: Independent status; Compensation Committee chairship; no interlocks; strong attendance culture; transparent pay practices with multi‑year EBITDA/ROE/TSR alignment; robust director ownership guidelines and anti‑hedging/pledging policy .
- Shareholder signals: Strong 2024 shareholder support for his re‑election and high say‑on‑pay approval counts indicate investor confidence in compensation oversight under his chairship .
- Potential conflicts/red flags: None disclosed for Mr. Quiroz. Notable related‑party exposures exist elsewhere on the board (Mozina’s leasing/sourcing; Walters’ spousal relationship with CEO), but not tied to Mr. Quiroz .
- Ownership alignment: Ownership guidelines are stringent; individual compliance status by valuation is not specifically disclosed; holdings are unpledged and policy prohibits pledging/hedging .
Overall, Mr. Quiroz’s tenure, independence, and chair role on the Compensation Committee—combined with the Company’s clearly articulated performance‑based LTI design—support board effectiveness and pay‑for‑performance governance. No director‑specific conflicts or attendance concerns are disclosed for him .